Restoring balance.
Renewing life.

Akero is pioneering novel therapies to transform the lives of people living with serious metabolic diseases.
Learn More
Learn More

Advancing Efruxifermin (EFX) for NASH

Our flagship EFX program is designed to be a differentiated, potentially best-in-class treatment for non-alcoholic steatohepatitis (NASH)

Learn more

Ongoing Clinical Studies

We have multiple ongoing clinical trials to evaluate our investigational drug, EFX, as a treatment for NASH.

Learn more

Recent Press Releases from Akero

08/31/2023

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

08/28/2023

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

08/11/2023

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

View All

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions